Patents Assigned to Secretary, Department of
  • RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 1 (HPIV1) EXPRESSING A CHIMERIC RSV/HPIV1 F PROTEIN AND USES THEREOF
    Publication number: 20230287055
    Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.
    Type: Application
    Filed: January 31, 2023
    Publication date: September 14, 2023
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Ser.
    Inventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
  • Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase
    Patent number: 11752138
    Abstract: The disclosure provides methods of treating a patient having primary hyperoxaluria or idiopathic hyperoxaluria comprising administering a therapeutically effective amound of compound of the formula and pharmaceutically acceptable salts, solvates, and hydrates thereof to the patient. The variables, e.g. ring A, n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful inhibiting the conversion of glyoxylate to oxalate. When administered to a patient having a disease or disorder associated with elevated oxalate levels, such as PH type 1, type 2, or type 3 or idiopathic hyperoxaluria the compounds prevent or substantially reduce the amount and buildup of oxalate the patient's kidneys, bladder, urinary tract and other parts of the patient's body.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: September 12, 2023
    Assignees: VANDERBILT UNIVERSITY, THE UAB RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Matthew Hall, Daniel J. Urban, John Knight, Ross Holmes, Kyle David Wood, Alex Waterson, Victor M. Darley-Usmar, Leonard M. Neckers
  • Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3?-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
    Patent number: 11753627
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: September 1, 2020
    Date of Patent: September 12, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
  • Compounds and method for blocking transmission of malarial parasite
    Patent number: 11753408
    Abstract: Disclosed are compounds of formula (I) and formula (II): wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: September 12, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Loyola University of Chicago
    Inventors: Wenwei Huang, Hao Li, Wei Sun, Xiuli Huang, Paresma R. Patel, Hangmao Sun, Wei Zheng, Xiao Lu, Philip E. Sanderson, Myunghoon Kim, Meghan J. Orr, Gregory J. Tawa, Kim C. Williamson
  • LIVE ATTENUATED RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20230279362
    Abstract: Reported herein are novel recombinant respiratory syncytial viruses (RSV) having an attenuated phenotype. The recombinant RSV strains described here are suitable for use as live-attenuated RSV vaccines. Also provided are polynucleotide sequences capable of encoding the described viruses, as well as methods for producing and using the viruses.
    Type: Application
    Filed: June 4, 2021
    Publication date: September 7, 2023
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Peter Collins, Ursula Buchholz
  • SUPPRESSION OF UVEITIS BY SINGLE DOMAIN ANTIBODY
    Publication number: 20230279086
    Abstract: The present invention provides methods of treating and preventing uveitis in a subject using a single-domain antibody (sdAb), wherein the sdAb comprises the amino acid sequence as set forth in SEQ ID NO:1. In one aspect, the subject is a mammal such as a human. In another aspect, the sbAb is used in combination with one or more compounds. The uveitis treated by the invention can be sympathetic ophthalmia, birdshot retinochoroidopathy, Behcet's disease, Vogt-Koyanagi-Harada disease and ocular sarcoidosis.
    Type: Application
    Filed: December 21, 2022
    Publication date: September 7, 2023
    Applicants: Singh Biotechnology, LLC, The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Sunanda Singh, Charles E. Egwuagu
  • GENE THERAPY FOR COMBINED METHYLMALONIC ACIDEMIA/ACIDURIA AND HYPERHOMOCYSTEINEMIA/HOMOCYSTINURIA, COBALAMIN C TYPE, AND DEFICIENCY OF MMACHC
    Publication number: 20230277688
    Abstract: The present invention provides a synthetic MMACHC polynucleotide comprising a polynucleotide encoding MMACHC that is codon-optimized for expression in a human. Also provided is a polypeptide encoded by a synthetic MMACHC polynucleotide, an expression vector comprising a MMACHC gene sequence under the control of a chicken beta actin (CBA) promoter, and an expression vector comprising a synthetic MMACHC polynucleotide. Methods of treating cobalamin C deficiency and for detecting or tracking exogenous MMACHC are also provided.
    Type: Application
    Filed: November 17, 2022
    Publication date: September 7, 2023
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Charles P. Venditti, Jennifer L. Sloan
  • Development of dengue virus vaccine components
    Patent number: 11746335
    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: September 5, 2023
    Assignee: The Government of the United States of American, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
  • Non-aggregating heptamethine cyanine fluorophores for in vivo imaging
    Patent number: 11746086
    Abstract: Heptamethine cyanine fluorophore conjugates and conjugate precursors are disclosed. Methods of using the conjugates and conjugate precursors are also disclosed. The disclosed conjugates are neutral zwitterionic molecules and exhibit little or no aggregation.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: September 5, 2023
    Assignee: The USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Martin John Schnermann, Michael Philip Luciano, Roger Rauhauser Nani
  • SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING
    Publication number: 20230271998
    Abstract: Disclosed herein are embodiments of a solid support suitable for synthesizing nucleic acid sequences. The solid support may have a structure according to Formula I, where CPG is controlled pore glass, and m, n, x, y, R1 and R2 are as defined herein. Also disclosed are methods for making and using the solid support, kits including solid support, and a universal linker phosphoramidite suitable for use in the solid support.
    Type: Application
    Filed: June 28, 2021
    Publication date: August 31, 2023
    Applicant: United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Serge L. Beaucage, Andrzej M. Grajkowski
  • HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION
    Publication number: 20230272038
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with aspartic acid. The TCRs may recognize G12D RAS presented by an HLA-DR heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: July 13, 2021
    Publication date: August 31, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Noam Levin, Rami Yoseph, Gal Cafri, Steven A. Rosenberg
  • DREADD actuators
    Patent number: 11739063
    Abstract: Disclosed is a compound of formula (I) in which R1, R2, and R3 are as described herein. Also provided are pharmaceutical compositions comprising the compound of formula (I) and methods of using the compound of formula (I), including a method of treating a disease or disorder and a method for effectuating a G-protein coupled receptor (GPCR)-mediated response in a subject.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: August 29, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Johns Hopkins University
    Inventors: Jordi Bonaventura, Juan Luis Gomez, Andrew Horti, Feng Hu, Michael Michaelides, Martin Pomper, Marta Sanchez-Soto
  • PREFERENTIAL GENERATION OF iPSC CARRYING ANTIGEN SPECIFIC TCRs FROM TUMOR INFILTRATING LYMPHOCYTES
    Publication number: 20230265508
    Abstract: Disclosed are methods for reprogramming cancer-reactive T cells into iPSC cells as well as methods utilizing such cells for the identification of cancer-antigen specific TCRs and the treatment of cancer.
    Type: Application
    Filed: August 20, 2021
    Publication date: August 24, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Raul E. Vizcardo, SM Rafiqul Islam, Naritaka Tamaoki, Takuya Maeda, Nicholas P. Restifo
  • TIME EFFICIENT MULTI-PULSED FIELD GRADIENT (MPFG) MRI WITHOUT CONCOMITANT GRADIENT FIELD ARTIFACTS
    Publication number: 20230266418
    Abstract: Diffusion sensitizing gradient pulse pairs are prescribed in a manner to mitigate effects of concomitant gradient artifacts. Measured MR signals generated by applying a plurality of diffusion sensitizing gradient matrices are obtained and processed to determine a second order mean diffusion tensor and a fourth order covariance tensor. Quantities derived from these tensors are measured and mapped within an imaging volume which describe features of diffusion anisotropy and heterogeneity within each imaging voxel.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 24, 2023
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Magdoom Mohamed Kulam Najmudeen, Peter J. Basser, Michal E. Komlosh
  • ENHANCED CHEMILUMINESCENT ENZYME-LINKED IMMUNOSORBENT ASSAY FOR DETECTION OF ANTIBODIES AGAINST BABESIA MICROTI
    Publication number: 20230266306
    Abstract: Identification of immunodominant Babesia microti antigens using genome-wide immunoscreening is described. Candidate antigens were screened against sera from patients with clinical babesiosis. Also described are diagnostic assays with high sensitivity and specificity for detecting B. microti-specific antibodies in patient samples using the identified immunodominant antigens.
    Type: Application
    Filed: March 21, 2023
    Publication date: August 24, 2023
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Sanjai Kumar, Nitin Verma, Ankit Puri
  • METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR-REACTIVE T CELLS FROM TUMOR
    Publication number: 20230265387
    Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample; (b) specifically selecting CD8+ T cells that express any one or more of TIM-3, LAG-3, 4-1BB, and PD-1 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.
    Type: Application
    Filed: January 6, 2023
    Publication date: August 24, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY
    Publication number: 20230258635
    Abstract: Disclosed are methods of obtaining a cell population enriched for T cells with a phenotype, the method comprising: (a) obtaining a bulk population of T cells from a tumor sample of a patient; (b) specifically selecting T cells with a phenotype comprising markers CD3+, CD39?, and CD69? from the bulk population; and (c) separating the cells selected in (b) from cells which lack the phenotype to obtain a cell population enriched for T cells with the phenotype. Related methods of treating or preventing cancer, methods of selecting a therapy for a cancer patient, and methods for predicting the clinical response to immunotherapy in a cancer patient are also disclosed. Isolated or purified cell population obtained according to the methods and related pharmaceutical compositions are also disclosed.
    Type: Application
    Filed: September 8, 2021
    Publication date: August 17, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Frank J. Lowery, III, Sri Krishna, Paul F. Robbins, Steven A. Rosenberg, Gregoire Y. Altan-Bonnet
  • REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY
    Publication number: 20230257756
    Abstract: The disclosure provides methods for carrying out Real Time Cellular Thermal Shift Assays (RT-CETSA). Also provided are molecular constructs and protein constructs for use in such assays and devices suitable for carrying out such assays.
    Type: Application
    Filed: August 9, 2021
    Publication date: August 17, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Mark J. Henderson, Michael H. Ronzetti, Bolormaa Baljinnyam, Tino W. Sanchez, Samuel G. Michael, Ashley E. Owens, Anton Simeonov
  • DIGITAL MICROSCOPE WITH ARTIFICIAL INTELLIGENCE BASED IMAGING
    Publication number: 20230258918
    Abstract: The invention relates to the domain of microscope based imaging. The invention provides methods and apparatuses for providing improved microscope based digital imaging solutions that are capable of providing high quality images with a high level of image detail. The invention additionally provides solutions for artificial intelligence based controlling of a digital microscope's imaging functions to enable bright field/dark field imaging functionality to be combined with spectroscopic functions to obtain higher detail and more meaningful information about a specimen sample.
    Type: Application
    Filed: July 7, 2021
    Publication date: August 17, 2023
    Applicant: Secretary, Department of Biotechnology
    Inventors: Ashutosh Patra, Praveen Kumar, Tushar Sehgal
  • HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
    Publication number: 20230257440
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with valine. The TCRs may recognize G12V RAS presented by an HLA-DR heterodimer. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 17, 2023
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Noam Levin, Frank J. Lowery, III, Maria R. Parkhurst, Steven A. Rosenberg